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Introduction: Lung cancer has become a disease of elderly. How-
ever, there are limited data describing the specific therapies, includ-
ing epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI), for octogenarians with advanced non-small cell lung
cancer (NSCLC). This study is to characterize the treatment modal-
ities and outcomes for octogenarians with advanced NSCLC and to
investigate the impact of EGFR-TKI on survival.
Methods: From January 2000 to December 2006, patients with
NSCLC aged 80 years or older with stage IIIB or IV disease at
National Taiwan University Hospital were included. The medical
records were reviewed and analyzed. A Cox proportional hazard
model was used to calculate the hazard ratio and its 95% confidence
interval for gender, performance status, histologic types, disease
stages, smoking history, comorbidities, and initial treatment modal-
ities.
Results: A total of 203 patients were included. Sixty-five patients
(32.0%) were treated with EGFR-TKI as the first-line therapy, and
all of them were admitted after 2003. After 2003, the proportion of
supportive care significantly decreased (p  0.001), whereas those
of chemotherapy and radiotherapy showed no significant change.
There was a trend of an increase in median survival from 2003
(2000: 37 days, 2001: 62 days, 2002: 69 days, 2003: 110 days, 2004:
85 days, 2005: 188 days, and 2006: 195 days). When compared with
those who received supportive care only, patients who received
EGFR-TKI therapy had a significantly better prognosis (hazard
ratio: 0.56, 95% confidence interval: 0.40–0.80), whereas no sig-
nificant survival benefit was found in patients who received chemo-
therapy or radiotherapy.
Conclusion: For octogenarians with advanced NSCLC, EGFR-TKI
may play an important role in the initial treatment modalities.
Further large-scale elderly specific clinical trials for EGFR-TKI as
first-line therapy are warranted.
Key Words: Lung cancer, Epidermal growth factor receptor, El-
derly, Survival.
(J Thorac Oncol. 2010;5: 82–89)
Lung cancer is the leading cause of cancer deaths world-wide, including Taiwan.1,2 In the 90s, more than 50% of
patients with advanced non-small cell lung cancer (NSCLC)
at diagnosis were older than 65 years.3 According to the
surveillance, epidemiology, and end results data in the United
States, the median age of patients with lung cancer is 71 years
(70 years for men and 71 years for women).4 In Taiwan, the
median age of patients with lung cancer is 71 years for men
and 68 years for women.5 Lung cancer has become a disease
of the elderly.
For elderly patients, deterioration in cardiovascular
and pulmonary functions may be the major concerns while
considering curative surgery and radiotherapy. The decline
of drug metabolizing capability and reduced bone marrow,
liver, and renal functional reserves may limit the use of
chemotherapy.6 Thus, the optimal treatment for lung can-
cer in elderly patients may be different from those in
younger patients.
In most clinical trials for lung cancer, there is a signif-
icant underrepresentation of elderly patients.7–9 The elderly
specific studies for lung cancer are relatively few. Data for
elderly patients usually come from subset analyses of large-
scale clinical trials. A review reported that selected elderly
patients with local and locally advanced lung cancer could
tolerate surgery, radiotherapy, and chemoradiation.10 Other
studies also demonstrated that selected elderly patients could
tolerate and benefit from chemotherapy.11–14 However, there
are limited data describing the specific therapies for patients
aged 80 years or older.
A study using the surveillance, epidemiology, and end
results database from 1988 to 2003 showed that patients aged
80 years or older accounted for 14% of all patients with lung
cancer.15 In Taiwan, the proportion of patients with lung
cancer aged 80 years or older increased from 7.3% in 1995 to
15.1% in 2005.5 However, the proportion of patient aged 70
to 79 years did not change significantly (32.5% in 1995 and
35.5% in 2005).5 The increase of octogenarians with lung
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cancer raises the importance of finding an optimal treatment
for these very elderly patients.
Previously, we found that NSCLC accounted for the
majority of patients with lung cancer aged 80 years or older,
and most of them were stage III or IV.16 Little is known about
the treatment outcomes and prognostic factors in octogenar-
ian with advanced NSCLC. Epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKI), including gefitinib
and erlotinib, have shown to be effective in treating
NSCLC.17,18 A study comparing gefitinib and a placebo in
patients with NSCLC refractory to chemotherapy showed a
survival gain with gefitinib therapy in the subgroup of
Asians.19 Therefore, this study was to characterize the distri-
bution and influence on outcomes of antitumor treatment
modalities in octogenarians with advanced NSCLC, with a
special interest in EGFR-TKI that was approved in Taiwan in
2003.
METHODS
Patients
Patients with a diagnosis of lung cancer admitted to the
National Taiwan University Hospital during the period be-
tween January 2000 and December 2006 were identified from
a computer registration database by using the International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation, coding system. The patients were included if they
were aged 80 years or older at diagnosis and with advanced
stages of NSCLC. The diagnosis of NSCLC was based on
histologic examination of biopsy specimens or on fine needle
aspiration cytology. Exclusion criteria included a diagnosis of
other types of cancer established before lung cancer and a
clinical diagnosis without biopsy or aspiration of lung tu-
mors. The Institutional Review Board of the National Taiwan
University Hospital approved this study.
Data Collection
The medical records of all patients included were re-
viewed for age, gender, performance status (PS), histology of
cancer, disease stages, comorbidities, history of smoking,
treatment modalities, and date of death or last visit. Eastern
Cooperative Oncology Group (ECOG) PS was obtained ret-
rospectively from the charts recorded by the physicians or the
nurses. The ECOG PS scores were determined by the records
on admission for the patients’ activity of daily life and the
extent of dependence. The disease stage was determined by a
combination of surgical and pathologic findings according to
the current tumor, node, metastasis system for NSCLC,20 if
the patient underwent lung tumor resection. For those who
did not undergo surgical intervention, clinical staging was
performed according to the patients’ computed tomography
scan of the thorax, including the upper part of abdomen, brain
computed tomography scan, and radionuclide scanning of the
bone. Those with stage IIIB or IV were defined as patients
with advanced stages. Histologic analysis of the tumor was
based on the World Health Organization classification.21 For
initial treatment modalities, antitumor treatments included
chemotherapy, palliative radiotherapy, and EGFR-TKI ther-
apy. If the patients did not receive any antitumor treatment,
they were defined as patients receiving supportive care only.
Epidermal Growth Factor Receptor Gene
Mutation Analysis
We reviewed the gene epidermal growth factor receptor
(EGFR) mutation status of the lung cancer specimens, when-
ever available, from those with EGFR-TKI therapy. In brief,
DNA was derived from tumors embedded in paraffin blocks
using a QIAmp DNA Mini kit (Qiagen, Valencia, CA).
EGFR exons 18, 19, 20, and 21 were amplified by nested
polymerase chain reaction (PCR), using specific primers. The
primers and amplification conditions have been described
previously.22 The resulting PCR amplicons were purified and
sequenced using the BigDye Terminator kit (Applied Biosys-
tems, Foster City, CA) and an ABI Prism 3700 DNA Ana-
lyzer (Applied Biosystems). PCR amplicons were sequenced
in both sense and antisense directions. Specimens with EGFR
mutations were confirmed twice. Mutations were also
checked against the single nucleotide polymorphism data-
base.
Statistical Analysis
Patient characteristics were compared using a 2 test.
Comparisons between patient groups of different PS in types
of treatment were tested using a 2 method and Pearson’s test.
All reported p values were two sided. Survival was defined as
the time between the date of diagnosis and the date of death
or last visit. The patients were followed until June 30, 2008,
or till the date of their death. Survival functions were ana-
lyzed by the Kaplan-Meier method. Log-rank tests were
performed to compare the difference in survival between
patients groups in terms of different variables. A Cox pro-
portional hazard model was used to calculate the hazard ratio
(HR) and its 95% confidence interval (CI) for age, gender,
PS, histology of cancer, disease stage, smoking history,
medical comorbidities, and treatment modalities. Univariate
analyses were conducted to examine the unadjusted associa-
tions between patient groups with each individual indepen-
dent variable. All factors significantly associated with patient
survival in univariate analyses (p  0.10) were included in
the multivariate model. Variables that remained significant
after multivariate adjustment were retained in the final model.
RESULTS
Clinical Characteristics
From January 2000 to December 2006, there were a
total of 3639 patients with a diagnosis of lung cancer iden-
tified from the computer registration database. A total of 410
patients aged 80 years or older had histologically or cytolog-
ically proven lung cancer. Among them, 203 with advanced
stages NSCLC were included.
The clinical characteristics of the 203 patients are listed
in Table 1. The median age was 83 years (range: 80–96
years), with 114 (56.2%) male patients. There were 116
patients (57.1%) with PS 0 to 2. Eighty-three patients
(40.9%) had a history of smoking, with seven (7.9% of all
female patients) being women and 76 (66.7% of all male
patients) men. Hypertension (56.7%) was the most common
comorbidity, followed by heart disease (24.1%), including
congestive heart failure and coronary artery disease, diabetes
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mellitus (19.8%), chronic obstructive pulmonary disease
(COPD) (13.3%), renal insufficiency (creatinine 1.5 mg/dl
at diagnosis) (12.3%), and diseases of the central nerve
system (5.5%), including dementia and previous stroke.
For histologic distribution, adenocarcinoma (69.0%)
was the most frequent histologic type. Female patients had a
greater proportion of adenocarcinoma (women versus men,
85.4% versus 56.1%, p  0.001) and a smaller proportion of
squamous cell carcinoma (4.5% versus 29.0%, p  0.001).
There were 57 patients (28.1%) with stage IIIB and 146
patients (71.9%) with stage IV disease.
Treatment Modality
Among the 203 patients, 93 (45.8%) received support-
ive care only. Regarding the initial antitumor therapy, 65
patients (32.0%) received EGFR-TKI therapy, 17 (8.4%)
received chemotherapy, and 28 (13.8%) received palliative
radiotherapy (Table 1). The distribution of treatment modal-
ities in different time periods is demonstrated in Table 2. All
the patients receiving EGFR-TKI therapy as the first-line
treatment had been registered since 2003. The proportion of
supportive care had significantly decreased since 2003
(2000–2002: 74.5%, 2003–2006: 37.2%, p  0.001),
whereas the proportion of chemotherapy (2000–2002: 10.6%,
2003–2006: 7.7%, p  0.523) and radiotherapy (2000–2002:
14.9%, 2003–2006: 13.5%, p  0.803) showed no significant
change.
Among the 65 patients with EGFR-TKI therapy, 60
received gefitinib therapy, and five received erlotinib therapy.
Among the 17 patients receiving chemotherapy, 14 received
monotherapy, including 10 with gemcitabine, two with vi-
norelbine, and two with paclitaxel. Three patients received
combination regimens, including two with vinorelbine plus
cisplatin and one with gemcitabine plus vinorelbine. For the
28 patients who received palliative radiotherapy, three re-
ceived whole brain radiotherapy, three for bone metastasis,
and 22 for palliation of thoracic tumors.
We investigated the correlation between the PS and the
treatment modalities (Table 3). For the patients with PS 0 to
2, 42 (36.2%) received only supportive care, and 51 patients
(58.6%)with PS 3 to 4 received only supportive care (p 
0.002). The patients with PS 0 to 2 were more likely to
receive palliative radiotherapy (PS 0–2 versus 3–4, 19.0%
versus 6.9%, p  0.014) and chemotherapy (PS 0–2 versus
3–4, 12.9% versus 2.3%, p  0.007) than those with PS 3 to
4. The proportion of patients receiving EGFR-TKI was sim-
ilar in both PS subgroups (PS0–2 versus 3–4, 31.9% versus
32.2%, p  0.965).
Survival and Prognostic Factors
During the follow-up period, a total of 171 events of
death occurred (84.2%). There was a trend of an increase in
median survival from 2003 (2000: 37 days, 2001: 62 days,
2002: 69 days, 2003: 110 days, 2004: 85 days, 2005: 188
days, and 2006: 195 days; Figure 1). The median survival was
longer for patients admitted in 2003–2006 than in 2000–
2002; however, the difference was not statistically significant
TABLE 2. Distribution of Treatment Modalities in Patients
Registered during Different Time Periods
2000–2002, n (%) 2003–2006, n (%) p
Supportive care only 35 (74.5) 58 (37.2) 0.001
Palliative radiotherapy 7 (14.9) 21 (13.4) 0.803
Chemotherapy 5 (10.6) 12 (7.7) 0.523
EGFR-TKI 0 (0) 65 (41.7) —
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.
TABLE 3. Treatment Modalities for Patients with Different
Performance Status
PS 0–2, n (%) PS 3–4, n (%) p
Supportive care only 42 (36.2) 51 (58.6) 0.002
Palliative radiotherapy 22 (19.0) 6 (6.9) 0.014
Chemotherapy 15 (12.9) 2 (2.3) 0.007
EGFR-TKI 37 (31.9) 28 (32.2) 0.965
PS, performance status; EGFR-TKI, epidermal growth factor receptor-tyrosine
kinase inhibitor.
TABLE 1. The Clinical Characteristics of 203 Patients Aged
80 Years or Older with Advanced Non-small Cell Lung
Cancer
Clinical Characteristics n (%)
Median age (range) 83 (80–96)
Male 114 (56.2)
Performance status
0–1 85 (41.9)
2 31 (15.2)
3–4 87 (42.9)
Histology
Adenocarcinoma 140 (69.0)
Squamous cell carcinoma 37 (18.2)
Undifferentiated carcinoma 21 (10.3)
Large cell carcinoma 5 (2.5)
Clinical stage
IIIB 57 (28.1)
IV 146 (71.9)
Ever smoker 83 (40.9)
Comorbidity
Hypertension 115 (56.7)
Cardiac diseases 49 (24.1)
Diabetes mellitus 40 (19.8)
Chronic obstructive
pulmonary disease
27 (13.3)
Renal insufficiencya 25 (12.3)
CNS diseases 11 (5.5)
Initial treatment modalities
Supportive care only 93 (45.8)
Chemotherapy 17 (8.4)
Palliative radiotherapy 28 (13.8)
EGFR-TKI therapy 65 (32.0)
a Renal insufficiency denotes serum creatinine 1.5 mg/dl.
CNS, central nervous system; EGFR-TKI, epidermal growth factor receptor-
tyrosine kinase inhibitor.
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(2000–2002 versus 2003–2006, 62 versus 141 days, p 
0.154, Figure 2).
Concerning the survival difference in patient groups of
various treatment modalities, we found the median survival
was 58 days in patients who received supportive care only
and 148 days in patients who received any one of the
antitumor therapies (p  0.001, Figure 3). The median
survival was 115 days for patients who received palliative
radiotherapy, 156 days for patients who received chemother-
apy, and 222 days for those who received EGFR-TKI ther-
apy. No statistically significant difference was found among
the median survival of these three patient groups (p  0.76).
By univariate analysis, we found that male gender, poor
PS (PS 3–4), ever smoker, COPD, and renal insufficiency
were associated with a poor survival (Table 4). By multivar-
iate analysis, poor PS (HR: 2.15, 95% CI: 1.56–2.98) and
male gender (HR: 1.59, 95% CI: 1.16–2.17) were found to be
significantly associated with a worse prognosis than their
counter part (Table 5). Patients who received EGFR-TKI
therapy had a better survival than those who received sup-
portive care only (HR: 0. 56, 95% CI: 0.40–0.80). There was
no significant survival difference in patients who received
chemotherapy or radiotherapy compared with those who
received supportive care (Table 5).
The Association Between EGFR Mutation
and Overall Survival in Patients Treated with
EGFR-TKI
Among the 65 patients with EGFR-TKI therapy, there
were 25 with lung cancer specimens for EGFR mutation
analysis. Some of the patients were included in our previous
study.23 EGFR mutations were found in 13 patients (52.0%),
including seven L858R, one L858RT790M, one G719D,
and four exon 19 deletions. Among the patients with EGFR
mutation, there were 10 women (10 of 18, 55.6%) and three
men (3 of 7, 42.9%) (p  0.568). A total of 12 patients
(92.3%) with EGFR mutation were adenocarcinoma (p 
0.109). No significant difference was found between ever
smokers and nonsmokers in the frequency of EGFR mutation
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FIGURE 1. The median survival periods of octogenarians
with advanced non-small cell lung cancer at different year of
registration. There was a trend of an increase in median sur-
vival from 2003.
FIGURE 2. Survival analysis for patients diagnosed during
year 2003–2006 (n  156) and year 2000–2002 (n  47).
Divergence between the curves representing the two groups
of patients is not statistically evident, with survival time for
patients diagnosed during 2000–2002 shorter as determined
by log-rank test (2000–2002 versus 2003–2006, 62 days
versus 141 days, p  0.154).
FIGURE 3. Survival analysis for patients receiving antitumor
therapy (n  110) and receiving supportive care (n  93).
Divergence between the curves representing the two groups
of patients is evident, with survival time for patients with
supportive care significantly shorter as determined by log-
rank test (antitumor therapy versus supportive care, 148 ver-
sus 58 days, p  0.001).
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(4 of 6, 66.7% versus 9 of 19, 47.4%, p 0.409). Because the
tumor with T790M mutation may be resistant to EGFR-TKI
therapy, we excluded the patient with L858RT790M while
performing survival analysis.24 Patients with EGFR muta-
tions had a longer survival than those without EGFR muta-
tions (with versus without mutation, 425 versus 183 days).
However, the survival difference is not statistically signifi-
cant (p  0.086, Figure 4).
DISCUSSION
Our study demonstrated a decrease in the proportion of
supportive care and an increase in median survival after the
introduction of EGFR-TKI in 2003 for octogenarian with
advanced NSCLC. Patients who received EGFR-TKI therapy
had a better survival than those who received supportive care
only. PS 3 to 4 and male gender were significantly associated
with a poor prognosis.
Few reports have described the distribution of treatment
modalities in octogenarian with advanced NSCLC. A popu-
lation-based study for octogenarian with NSCLC demon-
strated that only 21% with stage III received the recommended
therapy and 16% with stage IV received chemotherapy.25 An-
other study included 70 octogenarians with stage III or IV
NSCLC and showed that 36% received chemotherapy and 27%
received oral target therapy alone.26 Our study demonstrated a
relatively high proportion of supportive care (45.8%) and
a low proportion of chemotherapy (7.9%). The fear of side
effects of chemotherapy might be the major reason to
choose supportive care.
After EGFR-TKI, a more tolerable systemic therapy
was introduced in 2003, and the treatment pattern changed.
The proportion of supportive care decreased significantly,
whereas the proportion of chemotherapy and radiotherapy
changed little. The median survival increased after 2003. A
recent study in Japan also showed that overall survival was
FIGURE 4. Survival analysis for patients receiving epidermal
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
therapy with EGFR mutation (n  12) and without EGFR mu-
tation (n  12). Divergence between the curves represent-
ing the two groups of patients is not statistically evident,
with survival time for patients without EGFR mutation shorter
as determined by log-rank test (with versus without muta-
tion, 425 versus 183 days p  0.086).
TABLE 4. Univariate Analysis of Factors Associated with
Survival in Octogenarians with Advanced Non-small Cell
Lung Cancer (n  203)
Clinical Characteristics
Hazard Ratio
(95% Confidence Interval) p
Age 1.02 (0.98–1.06) 0.25
Male gender 1.46 (1.08–1.99) 0.01
Performance status
0–2 1
3–4 2.03 (1.49–2.77) 0.0001
Histologic type
Adenocarcinomaa 1
Squamous cell carcinoma 1.19 (0.81–1.76) 0.37
Undifferentiated carcinoma 1.37 (0.84–2.24) 0.21
Large cell carcinoma 1.32 (0.54–3.24) 0.54
Clinical stage
IIIB 1
IV 0.98 (0.71–1.37) 0.92
Ever smoker 1.44 (1.06–1.95) 0.02
Medical comorbidity
Hypertension 0.95 (0.70–1.23) 0.75
Diabetes mellitus 1.07 (0.74–1.55) 0.73
Chronic obstructive
pulmonary disease
1.83 (1.21–2.478) 0.004
Cardiac diseases 1.22 (0.87–1.72) 0.25
Renal insufficiency 1.58 (1.02–2.46) 0.04
CNS diseases 1.29 (0.68–2.45) 0.44
Treatment
Supportive care onlya 1 —
Chemotherapy 0.62 (0.35–1.09) 0.10
Radiotherapy 0.63 (0.39–1.00) 0.05
EGFR-TKI therapy 0.54 (0.38–0.76) 0.0005
a Reference group.
CNS, central nervous system; EGFR-TKI, epidermal growth factor receptor-
tyrosine kinase inhibitor.
TABLE 5. Multivariate Analysis of Factors Associated with
Survival in Octogenarians with Advanced Non-small Cell
Lung Cancer (n  203)
Characteristics Hazard Ratio (95% Confidence Interval)
Male gender 1.59 (1.16–2.17)
Performance status
0–2 1
3–4 2.15 (1.56–2.98)
Treatment modalities
Supportive care onlya 1
Chemotherapy 0.75 (0.42–1.34)
Radiotherapy 0.64 (0.40–1.04)
EGFR-TKI therapy 0.56 (0.40–0.80)
a Reference group.
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.
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longer for patients with advanced lung adenocarcinoma after
gefitinib approval, especially for patients with EGFR muta-
tions.27 In this hospital-based study, we demonstrated the
introduction of EGFR-TKI therapy was associated with the
survival improvement for Taiwanese octogenarian with ad-
vanced NSCLC. Further population-based studies might be
warranted.
Few studies reported on the treatment efficacy of
EGFR-TKI in the elderly patients. A subgroup analysis in
BR. 21 study showed that elderly patients treated with erlo-
tinib had similar gains in survival and quality of life as
younger patients.28 A phase II trial of chemo-naive elderly
patients (n  80) treated with erlotinib for advanced NSCLC
showed a median time to progression of 3.5 months and a
median survival of 10.9 months.29 Another phase II trial with
gefitinib treatment for chemo-naive patients with NSCLC
aged 75 years or older showed a median survival of 10
months.30 One study comparing gefitinib with vinorelbine in
chemo-naive patients with NSCLC showed no statistical
difference in efficacy, but there was better tolerability with
gefitinib.31 Using multivariate analyses, our study showed a
survival benefit for octogenarians received EGFR-TKI than
those who received supportive care. Further prospective
large-scale randomized trials are warranted to compare
EGFR-TKI with chemotherapy in elderly patients, especially
for octogenarians.
A deletion in exon 19 and the exon 21L858R mutation
of EGFR have been shown to predict good treatment response
for EGFR-TKI.32–36 Some studies have also demonstrated the
association between EGFR mutation and good clinical out-
come in patients with NSCLC treated with gefitinib.23,33,37,38
However, there has been little discussion regarding EGFR
mutations and survival in elderly patients. Jackman et al.29
reported that EGFR mutation was strongly correlated with
disease control, prolonged time to disease progression, and
survival in elderly patients treated with erlotinib.29 However,
the case number is small (n  9, aged 70–79 years). Ebi et
al.30 also showed a better treatment response in elderly
patients with NSCLC treated with gefitinib. A more recent
phase II study demonstrated a median survival of 17.8
months in patients with NSCLC with poor PS or old age, who
had EGFR mutation and received gefitinib therapy as the
initial treatment.39 Our study is the first study to focus on
EGFR mutations in octogenarians with NSCLC. For those
who received EGFR-TKI therapy, the survival is longer for
those with EGFR mutation compared with those without
EGFR mutation, although the difference is not statistically
significant. Because elderly patients may have less chance to
receive the second-line treatment than younger patients be-
cause of the likely deterioration of PS and the intolerance of
treatment-related toxicities, EGFR mutations might be an
important prognostic factor, especially for octogenarians with
advanced NSCLC.
Although previous trials for elderly patients have dem-
onstrated the benefits of chemotherapy on survival and qual-
ity of life,11,40–42 very few data have been reported regarding
patients aged 80 years or older. A retrospective study dem-
onstrated that during the period from 1997 to 2004, patients
with advanced NSCLC older than 80 years (n  46) received
systemic therapy, including 20 who received platinum-based
chemotherapy. The response rate, median progression free
survival, overall survival, and toxicity were similar for pa-
tients aged older than 80 years and aged 80 years or less.43 In
the age-specific subset analysis of trial ECOG 1594 (n 
1139) for NSCLC, only nine patients were aged 80 years or
older. These patients had a shorter time to progression and
survival than that of the patients aged 70 to 79 years, with
only one being able to receive three cycles of chemothe-
rapy.44 Another recent study for octogenarian with NSCLC
(n  20) showed a median survival of 10 months with an
acceptable toxicity profile.45 Our study failed to demonstrate
a statistically survival benefit for patients received chemo-
therapy (n  17), which may be due to small patient number.
These octogenarians in clinical trials were all with good PS,
hematological, liver, and renal function. They might repre-
sent only a small proportion of octogenarians. Whether sys-
temic chemotherapy can be beneficial for octogenarians with
advanced NSCLC requires further large-scale prospective
investigations.
The clinical characteristics of our study population, a
cohort of Asian patients, are different from those of white
patients. There is only 13% of patients who had COPD.
However, a recent report in the Netherlands had shown that
30% of male and 25% of female elderly patients with NSCLC
had COPD.46 Only 41% of our patients had a history of
smoking, which is different from a cohort of octogenarians
with NSCLC in the United States.26 In that report, 91% of
patients had a history of smoking. These differences may be
due to the high proportion of nonsmoker in female patients
(92%) in our study. Because Asian series of patients are quite
different from white, conclusions from Asian studies cannot
be fully applied to white patients.
Comorbidity has been demonstrated as a prognostic
factor in the previous reports. A recent study showed that
Charlson comorbidity index score1, a validated measure of
patient comorbidity that is weighted according to the influ-
ence of comorbidity on overall mortality, could be associated
with a poorer survival for patients with NSCLC.47 Another
study by Colinet et al.48 demonstrated that Simplified Comor-
bidity Score, a more informative scoring system including
only seven variables, could be of prognostic value in patients
with NSCLC. In our study, some comorbidities are shown to
be associated with poorer prognosis in univariate analysis,
such as COPD and renal insufficiency. However, these co-
morbidities were not associated with a poorer outcome in
multivariate analysis. In this study, because of retrospective
design, the comorbidity scores could not be determined for all
patients. Because octogenarians frequently have multiple co-
morbidities, a prospective evaluation of the comorbidity
scores for predicting the prognosis in octogenarians with
NSCLC is warranted.
Gender was demonstrated as an independent prognostic
factor, which is compatible with the results in our previous
study.16 Previous population-based studies have demonstrated
a favorable outcome in women.49–51 However, the cause of a
better prognosis in females regardless of staging and treat-
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ment modalities remains unclear. Recently, there have been
studies on the association between estrogen receptor (ER)
expression and lung cancer prognosis. In NSCLC, the expres-
sion of ER-alpha may be associated with a worse prognosis,
whereas ER-beta overexpression could be a significantly
favorable prognostic factor.52–54 However, the hormone sta-
tus in both genders of such elderly patients might be similar.
There might be other factors associated with the survival
difference between genders for patients aged 80 years or
older.
There are several limitations in our study. First, this is
a retrospective study. The patients included might represent a
small proportion of octogenarians with NSCLC who had
clinical conditions good enough to establish a histologic or
cytologic diagnosis. The patient number may be underesti-
mated. Second, the data including the dose and adjustment
during treatment including EGFR-TKI and chemotherapy
were not available. Third, the case numbers in the patient
groups of palliative radiotherapy and chemotherapy were
small for subgroup analyses. The data should be interpreted
carefully. Fourth, the PS of the patients was retrospectively
evaluated by medical records. The ECOG PS scores were
determined by the record on admission for the patients’
activity of daily life and the extent of dependence. The
number of patients with PS 3 to 4 might be underestimated if
the patients’ condition deteriorated rapidly before cancer
treatment.
In conclusion, for octogenarians with advanced
NSCLC, EGFR-TKI may play an important role in the initial
treatment modalities. When compared with supportive care,
EGFR-TKI therapy provides a survival benefit. Further el-
derly specific clinical trials for octogenarian with EGFR-TKI
are warranted.
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